When will Breezula be released and how does it compare to KX-826? Research/Science 7/31/2025
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
View this post in the Community →
Similar Community Posts Join
5 / 336 resultscommunity Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
community Switch from fin to dut and its worse
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
community What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
community Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Related Research
6 / 15 results
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Artificial Intelligence in Patient Education for Androgenetic Alopecia: A Comparative Study of ChatGPT, Gemini, and Deepseek R1
ChatGPT 4.0 and Gemini 1.5 Flash are effective for educating patients about androgenetic alopecia, while Deepseek R1 is less reliable.
research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Breezula, A Clinical Stage Topical Anti-Androgen, Promotes Dermal Papilla Inductivity And Reduces IL-6 Secretion In Balding Skin Samples Ex Vivo
Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.